These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9428596)

  • 1. Biodistribution of 123I-labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas.
    Kruijer PS; Klok RP; van den Koedijk CD; Blankenstein MA; Voskuil JH; Verzeijlbergen JF; Ensing GJ; Herscheid JD
    Nucl Med Biol; 1997 Nov; 24(8):719-22. PubMed ID: 9428596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
    Kawamura I; Lacey E; Tanaka Y; Nishigaki F; Manda T; Shimomura K
    Jpn J Cancer Res; 1994 Jun; 85(6):639-44. PubMed ID: 8063618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma.
    Kangas L; Haaparanta M; Paul R; Roeda D; Sipilä H
    Pharmacol Toxicol; 1989 Apr; 64(4):373-7. PubMed ID: 2526330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
    Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
    Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
    Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
    Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy.
    Young H; Carnochan P; Trivedi M; Potter GA; Eccles SA; Haynes BP; Jarman M; Ott RJ
    Nucl Med Biol; 1995 May; 22(4):405-11. PubMed ID: 7550016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-oestrogen action in experimental breast cancer.
    Jordan VC; Naylor KE; Dix CJ; Prestwich G
    Recent Results Cancer Res; 1980; 71():30-44. PubMed ID: 6768113
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours.
    Nicholson RI; Golder MP
    Eur J Cancer (1965); 1975 Aug; 11(8):571-9. PubMed ID: 816655
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiestrogen-binding sites in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors: relation to growth.
    Hwang PL; How BE
    Oncology; 1990; 47(6):495-500. PubMed ID: 2123025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
    Wei LL; Mangel WF; Katzenellenbogen BS
    J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.
    Robinson SP; Mauel DA; Jordan VC
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1817-21. PubMed ID: 2975594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization.
    Rijks LJ; van den Bos JC; van Doremalen PA; Boer GJ; de Bruin K; Janssen AG; van Royen EA
    Nucl Med Biol; 1998 Nov; 25(8):791-8. PubMed ID: 9863568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours.
    Daniel CP; Gaskell SJ; Nicholson RI
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):137-43. PubMed ID: 6420159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ; Kalet BT; Koch TH
    J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy for antitumor activity of the non-steroidal antiestrogens analog II and tamoxifen in 7,12-dimethylbenz[a] anthracene-induced rat mammary tumors.
    Pento JT; Magarian RA; King MM
    Cancer Lett; 1982; 15(3):261-9. PubMed ID: 6811128
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model.
    Robinson SP; Jordan VC
    Cancer Res; 1987 Oct; 47(20):5386-90. PubMed ID: 3115568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of tamoxifen in laboratory animals.
    Jordan VC; Allen KE; Dix CJ
    Cancer Treat Rep; 1980; 64(6-7):745-59. PubMed ID: 6775807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I labeling of tamoxifen and biodistribution studies in rats.
    Muftuler FZ; Unak P; Teksoz S; Acar C; Yolcular S; Yürekli Y
    Appl Radiat Isot; 2008 Feb; 66(2):178-87. PubMed ID: 17888670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
    Yang DJ; Li C; Kuang LR; Price JE; Buzdar AU; Tansey W; Cherif A; Gretzer M; Kim EE; Wallace S
    Life Sci; 1994; 55(1):53-67. PubMed ID: 8015349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
    Clemens JA; Bennett DR; Black LJ; Jones CD
    Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.